# EDGAR Filing Document

**Accession Number:** 0001464521
**File Stem:** 0001464521-25-000009
**Filing Date:** 2025-9
**Character Count:** 7240
**Document Hash:** 3f2a346b0b7466fd60bfa02c258da8e9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001464521-25-000009.hdr.sgml**: 20250910

**ACCESSION NUMBER**: 0001464521-25-000009

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250910

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20250910

**DATE AS OF CHANGE**: 20250910

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Heartflow, Inc.
- **CENTRAL INDEX KEY:** 0001464521
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 260506743
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0811

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42790
- **FILM NUMBER:** 251304669

**BUSINESS ADDRESS:**
- **STREET 1:** 331 E EVELYN AVENUE
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94041
- **BUSINESS PHONE:** 650-241-1221

**MAIL ADDRESS:**
- **STREET 1:** 331 E EVELYN AVENUE
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94041

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cardiovascular Simulation, Inc.
- **DATE OF NAME CHANGE:** 20090519

?xml version='1.0' encoding='ASCII'? htfl-20250910

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549** 

**FORM 8-K** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): September 10, 2025**

**Heartflow, Inc.**

**(Exact name of Registrant as Specified in Its Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42790** | **26-0506743** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**331 E. Evelyn Avenue**

**Mountain View, California 94041**

**(Address of Principal Executive Offices) (Zip Code)**

**(650) 241-1221**

**(Registrant's Telephone Number, Including Area Code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | HTFL | The Nasdaq Stock Market LLC<br>(Nasdaq Global Select Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 2.02 Results of Operations and Financial Condition.**

As previously disclosed, Heartflow, Inc. (the "Company") will participate at the Morgan Stanley 23<sup>rd</sup> Annual Global Healthcare Conference today, September 10, 2025. In connection with meetings with investors at the conference, the Company has published an Investor Presentation on its website as described in Item 7.01 below (the "Investor Presentation").

In the Investor Presentation, the Company discloses the following preliminary unaudited results of operations for the three months ended June 30, 2025, which were initially disclosed as ranges in the Company's Registration Statement on Form S-1 (File No. 333-288733) filed with the U.S. Securities and Exchange Commission ("SEC") in connection with the Company's initial public offering completed on August 11, 2025: (i) revenue is expected to be approximately $43.4 million, (ii) gross margin is expected to be approximately 75.5%, and (iii) operating expenses are expected to be approximately $46.5 million. In addition, the Company will disclose that its cash and cash equivalents balance was approximately $80.2 million as of June 30, 2025, which does not give effect to the net proceeds to the Company of approximately $333.0 million upon the closing of its initial public offering or the repayment in full during the three months ended September 30, 2025 of all amounts outstanding under the Company's Credit Agreement and Guaranty with Hayfin Services LLP and other parties thereto (comprising $114.1 million as of June 30, 2025) plus accrued interest and related fees thereon.

The financial information presented in this Item 2.02 is preliminary and unaudited based on the most recent information available to the Company's management as of the date hereof and does not reflect a comprehensive statement of the Company's financial results as of and for the three months ended June 30, 2025, which will be disclosed in the Company's Quarterly Report on Form 10-Q when filed with the SEC. Actual results for the three months ended June 30, 2025 may differ from this preliminary information as a result of completion of the quarterly review of the Company's consolidated financial statements for the three months ended June 30, 2025, including final adjustments, the review by the Company's independent registered public accounting firm, and other developments that may arise between now and the filing of the Quarterly Report on Form 10-Q.

**Item 7.01 Regulation FD Disclosure.**

In connection with the Morgan Stanley 23<sup>rd</sup> Annual Global Healthcare Conference, the Company is publishing the Investor Presentation on the Investors page of the Company's website at https://ir.heartflow.com.

The information contained in Items 2.02 and 7.01 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | HEARTFLOW, INC. | HEARTFLOW, INC. |
| Date: September 10, 2025 | By: | /s/ Vikram Verghese |
|  |  | **Vikram Verghese** |
|  |  | **Chief Financial Officer** |

---